Blueprint Medicines Corp (NAS:BPMC)
$ 104.26 -0.7 (-0.67%) Market Cap: 6.53 Bil Enterprise Value: 6.25 Bil PE Ratio: 0 PB Ratio: 21.02 GF Score: 72/100

Q4 2023 Blueprint Medicines Corp Earnings Call Transcript

Feb 15, 2024 / 01:00PM GMT
Release Date Price: $87.57 (+14.02%)
Operator

Good morning. My name is Drew. I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines fourth quarter and full year 2023 financial results conference call. (Operator Instructions) Thank you.

Jenna Cohen, you may begin your conference.

Jenna Cohen
Blueprint Medicines Corp - Senior Director & Head of IR

Thank you, Drew. Good morning, everyone. Welcome to Blueprint Medicines fourth quarter and full year 2023 financial and operating results conference call. This morning, we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as slides that will be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.

Joining me are Kate Haviland, Chief Executive Officer; Philina Lee, Chief Commercial Officer; Fouad Namouni, President, Research & Development; Mike Landsittel, Chief Financial Officer; Christina Ross,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot